Key result
High-sensitivity troponin testing is proposed as a novel strategy to predict cardiovascular risk in hypertension.
Why the study?
Cardiospecific troponins measured with high-sensitivity assays may allow early detection of minor myocardial cell injury in hypertension, but the predictive role and underlying mechanisms of troponin elevation in hypertension require discussion.
High-sensitivity cardiospecific troponins may serve as a valuable biomarker for predicting the risk of developing cardiovascular diseases and complications in patients with hypertension.
Should not yet change hypertension management; leaves open prospective validation of troponins for CV risk prediction.
It is well known that many pathological conditions of both cardiovascular diseases (CVDs) (coronary heart disease, myocardial infarction, arrhythmias, myocarditis, cardiomyopathy, etc.) and non-cardiac (sepsis, anemia, kidney diseases, diabetes mellitus, etc.) origin in the course of their development cause injury to contractile cardiac muscle cells - myocardial cells (MCs). One of the most sensitive and specific criteria for detecting MC injury are cardiospecific troponins (CTs), which are regulatory protein molecules that are released into the blood serum from MC upon their death or injury. Current methods for determining CTs are called high-sensitive ones, and their main advantage is a very low minimum detectable concentration (limit of detection) (average 1 - 10 ng/L or less), which allows early detection of minor MC injury at the earliest stages of CVDs, and therefore they can change the understanding of disease development mechanisms and open up new diagnostic possibilities. One of the most common and dangerous early diseases of the cardiovascular system is hypertension (HT). The novelty of this article lies in the discussion of a new diagnostic direction - predicting the risk of developing CVDs and their dangerous complications in patients with HT by determining the concentration of CTs. In addition, pathophysiological mechanisms underlying MC injury and the release of CTs into the bloodstream and the elimination of CTs into the urine are proposed. This information will contribute to additional fundamental and clinical research to verify the new diagnostic possibility of using CTs in clinical practice (for the management of patients with HT).
No takes yet. Share an insight, caveat, or question.
Aleksey M. Chaulin (2022) conducted a review in Hypertension. Cardiospecific troponins (CTs) measurement was evaluated. Determining high-sensitivity cardiospecific troponins in patients with hypertension is proposed as a novel diagnostic strategy for predicting the risk of cardiovascular diseases and complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: